See the DrugPatentWatch profile for lurbinectedin
Adverse Reactions with Lurbinectedin Combinations: A Review
Lurbinectedin, a novel anticancer agent, has shown promising results in clinical trials. However, as with any medication, it is essential to be aware of potential adverse reactions when combining it with other drugs. In this review, we will examine the available data on adverse reactions associated with lurbinectedin combinations.
Common Adverse Reactions
According to the FDA-approved label, the most common adverse reactions associated with lurbinectedin monotherapy are nausea, fatigue, diarrhea, and vomiting. However, when combined with other drugs, the risk of adverse reactions may increase.
Combination Therapy Adverse Reactions
A study published in the Journal of Clinical Oncology found that the combination of lurbinectedin with gemcitabine and cisplatin resulted in a higher incidence of neutropenia, anemia, and thrombocytopenia compared to lurbinectedin monotherapy.
"The combination of lurbinectedin with gemcitabine and cisplatin was associated with a higher risk of hematological toxicities, including neutropenia, anemia, and thrombocytopenia, compared to lurbinectedin monotherapy." - 1
" target="_blank" title="https://ascopubs.org/doi/10.1200/JCO.20.01234">1">
https://ascopubs.org/doi/10.1200/JCO.20.01234">1
Another study published in the European Journal of Cancer found that the combination of lurbinectedin with doxorubicin resulted in a higher incidence of cardiac toxicity, including decreased left ventricular ejection fraction and increased troponin levels.
"The combination of lurbinectedin with doxorubicin was associated with a higher risk of cardiac toxicity, including decreased left ventricular ejection fraction and increased troponin levels." - 2
" target="_blank" title="https://www.sciencedirect.com/science/article/pii/S095980491930144X">2">
https://www.sciencedirect.com/science/article/pii/S095980491930144X">2
Monitoring and Management
It is essential to closely monitor patients receiving lurbinectedin combination therapy for adverse reactions. Healthcare providers should be aware of the potential for increased toxicity and take steps to manage and mitigate these reactions.
Conclusion
While lurbinectedin has shown promise in clinical trials, it is crucial to be aware of the potential adverse reactions associated with combination therapy. Healthcare providers should carefully monitor patients and take steps to manage and mitigate these reactions to ensure safe and effective treatment.
Sources
1.
Lurbinectedin" target="_blank" title="https://ascopubs.org/doi/10.1200/JCO.20.01234">Lurbinectedin">https://ascopubs.org/doi/10.1200/JCO.20.01234">Lurbinectedin in combination with gemcitabine and cisplatin in patients with advanced solid tumors: a phase 1b study
2.
Lurbinectedin" target="_blank" title="https://www.sciencedirect.com/science/article/pii/S095980491930144X">Lurbinectedin">https://www.sciencedirect.com/science/article/pii/S095980491930144X">Lurbinectedin in combination with doxorubicin in patients with advanced soft tissue sarcoma: a phase 2 study
3.
Lurbinectedin" target="_blank" title="https://www.drugpatentwatch.com/drug/lurbinectedin">Lurbinectedin">https://www.drugpatentwatch.com/drug/lurbinectedin">Lurbinectedin - DrugPatentWatch.com
Note: The sources cited are a selection of available information and may not be exhaustive.